Revelation Biosciences Inc (REVB)
2.21
-0.05
(-2.21%)
USD |
NASDAQ |
Jun 14, 16:00
2.14
-0.07
(-3.17%)
After-Hours: 20:00
Revelation Biosciences Enterprise Value: -10.94M for June 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 14, 2024 | -10.94M |
| June 13, 2024 | -10.86M |
| June 12, 2024 | -10.86M |
| June 11, 2024 | -10.65M |
| June 10, 2024 | -10.83M |
| June 07, 2024 | -10.96M |
| June 06, 2024 | -10.94M |
| June 05, 2024 | -10.94M |
| June 04, 2024 | -11.38M |
| June 03, 2024 | -11.42M |
| May 31, 2024 | -11.40M |
| May 30, 2024 | -11.86M |
| May 29, 2024 | -11.81M |
| May 28, 2024 | -11.73M |
| May 24, 2024 | -11.56M |
| May 23, 2024 | -11.43M |
| May 22, 2024 | -11.24M |
| May 21, 2024 | -11.34M |
| May 20, 2024 | -11.30M |
| May 17, 2024 | -11.25M |
| May 16, 2024 | -11.51M |
| May 15, 2024 | -11.37M |
| May 14, 2024 | -11.54M |
| May 13, 2024 | -11.55M |
| May 10, 2024 | -11.19M |
| Date | Value |
|---|---|
| May 09, 2024 | -10.96M |
| May 08, 2024 | -10.91M |
| May 07, 2024 | -10.67M |
| May 06, 2024 | -10.71M |
| May 03, 2024 | -10.68M |
| May 02, 2024 | -10.71M |
| May 01, 2024 | -11.04M |
| April 30, 2024 | -11.11M |
| April 29, 2024 | -11.09M |
| April 26, 2024 | -10.99M |
| April 25, 2024 | -11.06M |
| April 24, 2024 | -11.14M |
| April 23, 2024 | -11.17M |
| April 22, 2024 | -11.20M |
| April 19, 2024 | -10.89M |
| April 18, 2024 | -10.89M |
| April 17, 2024 | -11.04M |
| April 16, 2024 | -11.43M |
| April 15, 2024 | -11.57M |
| April 12, 2024 | -11.16M |
| April 11, 2024 | -10.76M |
| April 10, 2024 | -10.78M |
| April 09, 2024 | -10.58M |
| April 08, 2024 | -10.31M |
| April 05, 2024 | -10.19M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-13.02M
Minimum
Apr 12 2023
118.19M
Maximum
Jan 12 2022
-1.012M
Average
-3.368M
Median
Enterprise Value Benchmarks
| CEL-SCI Corp | 65.10M |
| AIM ImmunoTech Inc | 15.35M |
| IGC Pharma Inc | 25.36M |
| NovaBay Pharmaceuticals Inc | 3.382M |
| Protalix BioTherapeutics Inc | 55.51M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.681M |
| Total Expenses (Quarterly) | 1.902M |
| EPS Diluted (Quarterly) | -2.46 |
| Earnings Yield | -1.40K% |